These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 7779607)

  • 1. DNA topoisomerase inhibitors.
    Capranico G; Giaccone G; Zunino F; Garattini S; D'Incalci M
    Cancer Chemother Biol Response Modif; 1994; 15():67-86. PubMed ID: 7779607
    [No Abstract]   [Full Text] [Related]  

  • 2. [DNA topoisomerases targeting anticancer agents and mechanism for acquirement of drug resistance].
    Furukawa M; Harada T; Tanaka T; Kuwano M
    Nihon Rinsho; 1997 May; 55(5):1096-102. PubMed ID: 9155159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance.
    Beck WT
    J Natl Cancer Inst; 1989 Nov; 81(22):1683-5. PubMed ID: 2553990
    [No Abstract]   [Full Text] [Related]  

  • 4. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
    Ellis AL; Nowak B; Plunkett W; Zwelling LA
    Cancer Chemother Pharmacol; 1994; 34(3):249-56. PubMed ID: 8004759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yeast as a genetic model system for studying topoisomerase inhibitors.
    Nitiss JL
    Adv Pharmacol; 1994; 29B():201-26. PubMed ID: 8996609
    [No Abstract]   [Full Text] [Related]  

  • 6. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
    Burris HA; Fields SM
    Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic approach for colorectal cancer with topoisomerase as a molecular target].
    Tsunoda T
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():472-5. PubMed ID: 14574938
    [No Abstract]   [Full Text] [Related]  

  • 8. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.
    Tan KB; Mattern MR; Eng WK; McCabe FL; Johnson RK
    J Natl Cancer Inst; 1989 Nov; 81(22):1732-5. PubMed ID: 2553992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA topoisomerase I inhibitors.
    Takimoto CH; Kieffer LV; Arbuck SG
    Cancer Chemother Biol Response Modif; 1997; 17():80-113. PubMed ID: 9551210
    [No Abstract]   [Full Text] [Related]  

  • 10. Topoisomerase inhibitors. A review of their therapeutic potential in cancer.
    Sinha BK
    Drugs; 1995 Jan; 49(1):11-9. PubMed ID: 7705211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA topoisomerase inhibitors as antifungal agents.
    Shen LL; Fostel JM
    Adv Pharmacol; 1994; 29B():227-44. PubMed ID: 8996610
    [No Abstract]   [Full Text] [Related]  

  • 12. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.
    Keshelava N; Groshen S; Reynolds CP
    Cancer Chemother Pharmacol; 2000; 45(1):1-8. PubMed ID: 10647494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA topoisomerase I poisons.
    Takimoto CH; Kieffer LV; Kieffer ME; Arbuck SG; Wright J
    Cancer Chemother Biol Response Modif; 1999; 18():81-124. PubMed ID: 10800479
    [No Abstract]   [Full Text] [Related]  

  • 14. The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase.
    Musk SR; Steel GG
    Br J Cancer; 1990 Sep; 62(3):364-7. PubMed ID: 2169851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
    Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH
    Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of topoisomerases in replication, transcription, and packaging of the linear adenovirus genome.
    Wong ML; Hsu MT
    J Virol; 1990 Feb; 64(2):691-9. PubMed ID: 2153235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
    Ling YH; Andersson BS; Nelson JA
    Cancer Biochem Biophys; 1990 Jan; 11(1):23-30. PubMed ID: 2159843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivation of topoisomerase I or II may lead to recombination or to aberrant replication termination on both SV40 and yeast 2 micron DNA.
    Levac P; Moss T
    Chromosoma; 1996 Oct; 105(4):250-60. PubMed ID: 8854885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
    Beck WT; Danks MK
    Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures.
    Pizao PE; Smitskamp-Wilms E; Van Ark-Otte J; Beijnen JH; Peters GJ; Pinedo HM; Giaccone G
    Biochem Pharmacol; 1994 Sep; 48(6):1145-54. PubMed ID: 7945408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.